ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson

CARY, N.C., September 10, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Sentynl Therapeutics, Inc., as the exclusive specialty pharmacy for ZOKINVY® (lonafarnib) in the United States. ZOKINVY is approved by the U.S. Food and Drug Administration (FDA) in patients 12 months of age and older with a body surface area of 0.39 m² and above to reduce risk of mortality in Hutchinson-Gilford Progeria Syndrome and for the treatment of processing-deficient Progeroid Laminopathies with either Heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations.

Hutchinson-Gilford Progeria Syndrome is an ultra-rare disease that causes premature aging and mortality in children. It affects a very small patient population, with an estimated prevalence in the United States of one in approximately 18-20 million people.¹ Sentynl is implementing this exclusive relationship with Biologics to ensure patients who are prescribed ZOKINVY in the United States receive the prompt intervention and management necessary to optimize their treatment.

“ZOKINVY is the first and only treatment option for Progeria,” said Ela Lourido, vice president and general manager, Specialty Pharmacy Solutions, McKesson. “This is a groundbreaking milestone, and Biologics is honored to be chosen as the specialty pharmacy provider by Sentynl to offer this important medication to patients who need it.”

Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.

For more information about ZOKINVY and the treatment of Hutchinson-Gilford Progeria Syndrome, please click here. For ZOKINVY’s full prescribing information, please click here.

¹Source:  https://www.progeriaresearch.org/wp-content/uploads/2024/04/FINAL-PRF-By-the-Numbers_-March-2024-1.pdf Accessed May 1, 2024

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 30 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.